Treatment for chronic myeloid leukaemia (CML)

The aim of treatment is to put chronic myeloid leukaemia (CML) into remission and to keep it in remission. The main treatment for CML is tyrosine kinase inhibitors (TKIs).

About treatment for chronic myeloid leukaemia (CML)

Chronic myeloid leukaemia (CML) usually develops very slowly, over several years. The main aim of treatment is to put CML into remission, and also keep it in remission. This means there are no signs of CML in your PCR blood test, and you feel well. There are different levels of remission.

Treatments for CML are very effective. Remission can usually be maintained for many years. For most people, CML can be well controlled, and it will not shorten their life.

We understand that having treatment can be a difficult time for people. We're here to support you. If you want to talk, you can:

Types of treatment for chronic myeloid leukaemia (CML)

Most people with CML are treated with targeted therapies called tyrosine kinase inhibitors (TKIs). You take them as tablets or capsules every day. There are several TKIs for CML.

  • Imatinib - this is the most commonly used TKI.
  • Nilotinib can be used in the chronic or accelerated phase if you cannot have imatinib.
  • Dasatinib can be used as a first treatment in the chronic phase, or if Imatinib is causing severe side effects or is not working.

Your doctors can usually change the TKI you have if the first one:

  • does not work
  • causes side effects that are difficult to manage
  • stops working.

Chemotherapy

When you are first diagnosed, you may have a very high level of white blood cells in your blood. If this happens, you may be given chemotherapy tablets for a few days or weeks before starting TKI treatment. Sometimes chemotherapy is given into a vein (intravenously) along with a TKI.

Occasionally chemotherapy is used if CML is in the blast phase. A combination of 3 or 4 drugs are given into a vein (intravenously).

Stem cell transplant

You may be offered a stem cell transplant if:

If your doctor thinks a stem cell transplant may be appropriate for you, they will discuss it with you in more detail. Stem cell transplants are only done in specialist cancer treatment centres. A stem cell transplant may cure some people with CML or put the CML into remission.

A stem cell transplant allows you to have much higher doses of chemotherapy.

If you have a stem cell transplant for CML, you will usually have stem cells from someone else who is a match for you (a donor). This is called a donor stem cell transplant or an allogeneic stem cell transplant.

A donor stem cell transplant aims to replace bone marrow that is no longer working properly with healthy stem cells from another person.

Interferon alpha

If other treatments have not worked, some people may be given interferon alpha in the chronic phase of CML. Interferon alpha is a protein that the immune system normally makes to help fight infection. Scientists can make this protein in the laboratory and use it as a treatment. In people with CML, it may help stop the bone marrow from producing too many white blood cells.

You have interferon alpha as an injection under the skin using a very fine needle. You or a family member or friend can be taught how to give these injections, so you can have them at home.

Interferon alpha can cause different side effects. Some are like the symptoms of flu. Some of these side effects can be reduced by taking a mild painkiller, such as paracetamol, before the injection. Your doctor can give you more advice.

The side effects are most noticeable with the first and second injections. They usually improve after that, but the tiredness may continue.

Interferon alpha and pregnancy

Doctors may also use interferon alpha for people who need CML treatment and are planning to get pregnant, or are already pregnant. Your doctor will talk to you about the possible benefits of this treatment and any possible risks to the developing baby.

Some doctors may recommend switching from interferon alpha to a TKI in the last 3 months of pregnancy. But this will depend on your situation. Your doctor will talk to you about what treatment may be right for you.

If you are planning to become pregnant, you should discuss this with your doctor. If you are pregnant, you should tell your doctor straight away.

Leukapheresis

Some people have a very high number of white blood cells in their blood when they are diagnosed with chronic myeloid leukaemia (CML). Doctors can remove some white blood cells from the blood using a process called leukapheresis.

If you are pregnant and have a high number of white cells in your blood, your haematologist might talk to you about having leukapheresis. This can be done to improve your symptoms and is safe to use during pregnancy.

Clinical trials for CML

Leukaemia research trials are done to try to find new and better treatments for leukaemia. Trials done on patients are called clinical trials. These may be done to:

  • test new treatments, such as new chemotherapy drugs or targeted therapies
  • look at new combinations of existing treatments, or change the way they are given to make them more effective or to reduce side effects
  • compare the effectiveness of drugs used to control symptoms
  • find out how cancer treatments work
  • find out which treatments are the most cost-effective.

Trials are the only reliable way to find out if a different type of treatment is better than what is already available.

About our information

This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer.

  • References

    Below is a sample of the sources used in our chronic myeloid leukaemia (CML) information. If you would like more information about the sources we use, please contact us at

    informationproductionteam@macmillan.org.uk

     

    National Institute for Health and Care Excellence (NICE). Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (Published 03 August 2022). Available from: www.nice.org.uk/guidance/ta813 (accessed July 2023).

     

    Smith, G, Apperley, J et al. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. British Journal of Haematology. 2022. Volume 191. Pages 171-193. Available from: onlinelibrary.wiley.com/doi/10.1111/bjh.16971 (accessed July 2023)

     

    Smith, G, Apperley, J et al. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. British Journal of Haematology. 2022. Volume 191. Pages 171-193. Available from: onlinelibrary.wiley.com/doi/10.1111/bjh.16971 (accessed July 2023)

Dr Anne Parker SME

Dr Anne Parker

Reviewer

Consultant Haematologist and Honorary Clinical Senior Lecturer

Queen Elizabeth University Hospital, Greater Glasgow and Clyde

Date reviewed

Reviewed: 01 January 2025
|
Next review: 01 January 2028
Trusted Information Creator - Patient Information Forum
Trusted Information Creator - Patient Information Forum

Our cancer information meets the PIF TICK quality mark.

This means it is easy to use, up-to-date and based on the latest evidence. Learn more about how we produce our information.

The language we use


We want everyone affected by cancer to feel our information is written for them.


We want our information to be as clear as possible. To do this, we try to:

  • use plain English
  • explain medical words
  • use short sentences
  • use illustrations to explain text
  • structure the information clearly
  • make sure important points are clear.

We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected.


You can read more about how we produce our information here.